Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Other Article (Clinical Trial;Journal Article)

The safety and immunogenicity of HIV-1MN recombinant gp160 (MN rgp160) vaccine in healthy, uninfected volunteers was tested in a double-blind study with a factorial design. By random assignment, 20 volunteers received three 200 micrograms doses of MN rgp160 and four volunteers received placebo at days 0, 28, and 168 or 0, 56, and 224. Of the 24 volunteers, 16 received 200 micrograms or 800 micrograms of MN rgp160 and two received placebo at day 532 (month 18). The vaccine was safe. It induced T cell memory measured by Th1 cytokine production and lymphocyte proliferation, and serum anti-MN rgp160 IgG (all subclasses) and IgA antibodies. Fifteen of 20 vaccinees developed neutralizing antibody. The regimen including immunizations on days 0, 28, and 168 followed by the 800 micrograms fourth dose was most immunogenic.

Full Text

Duke Authors

Cited Authors

  • Gorse, GJ; McElrath, MJ; Matthews, TJ; Hsieh, RH; Belshe, RB; Corey, L; Frey, SE; Kennedy, DJ; Walker, MC; Eibl, MM

Published Date

  • March 1, 1998

Published In

Volume / Issue

  • 16 / 5

Start / End Page

  • 493 - 506

PubMed ID

  • 9491504

International Standard Serial Number (ISSN)

  • 0264-410X

Digital Object Identifier (DOI)

  • 10.1016/s0264-410x(97)80003-5


  • eng

Conference Location

  • Netherlands